Risk of Fatigue and Hepatic and Metabolic Toxicities in Patients with Solid Tumors Treated with Everolimus: A Meta-Analysis

References

• O’Reilly T , McSheehyPM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl. Oncol.3(2), 65–79 (2010).
   PubMed Web of Science ®Google Scholar
• Houghton PJ . Everolimus. Clin. Cancer Res.16(5), 1368–1372 (2010).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O . Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside, J. Egypt. Natl Canc. Inst.25(4), 165–171 (2013).
   PubMedGoogle Scholar
• Abdel-Rahman O , AbdelwahabM, ShakerM, AbdelwahabS, ElbassionyM, EllithyM. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med. Oncol.30(3), 655 (2013).
   PubMed Web of Science ®Google Scholar
• Huober J , FaschingPA, HanuschCet al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab – results of the randomised GeparQuinto study (GBG 44). Eur. J. Cancer49(10), 2284–2293 (2013).
   PubMed Web of Science ®Google Scholar
• Afinitor® (everolimus) tablets for oral administration, package insert , Novartis Pharma AG, Stein, Switzerland (2012).
   Google Scholar
• Motzer RJ , EscudierB, OudardSet al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer116(18), 4256–4265 (2010).
   PubMed Web of Science ®Google Scholar
• Moher D , LiberatiA, TetzlaffJ, AltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol.62(10), 1006–1012 (2009).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute . Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006). http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Higgins JP , ThompsonSG, DeeksJJ, AltmanDG. Measuring inconsistency in meta-analyses. BMJ327(7414), 557–560 (2003).
   PubMed Web of Science ®Google Scholar
• Franz DN , BelousovaE, SparaganaSet al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled Phase 3 trial. Lancet381(9861), 125–132 (2013).
   PubMed Web of Science ®Google Scholar
• Ohtsu A , AjaniJA, BaiYXet al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, Phase III GRANITE-1 study. J. Clin. Oncol.31(31), 3935–3943 (2013).
   PubMed Web of Science ®Google Scholar
• Bissler JJ , KingswoodJC, RadzikowskaEet al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet381(9869), 817–824 (2013).
   PubMed Web of Science ®Google Scholar
• Bachelot T , BourgierC, CropetCet al. Randomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol.30(22), 2718–2724 (2012).
   PubMed Web of Science ®Google Scholar
• Baselga J , CamponeM, PiccartMet al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med.366(6), 520–529. (2012).
   PubMed Web of Science ®Google Scholar
• Pavel ME , HainsworthJD, BaudinEet al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study. Lancet378(9808), 2005–2012 (2011).
   PubMed Web of Science ®Google Scholar
• Yao JC , ShahMH, ItoTet al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med.364(6), 514–523 (2011).
   PubMed Web of Science ®Google Scholar
• Baselga J , SemiglazovV, van DamPet al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol.27(16), 2630–2637 (2009).
   PubMed Web of Science ®Google Scholar
• DerSimonian R , LairdN. Meta-analysis in clinical trials. Control. Clin. Trials7(3), 177–188 (1986).
   PubMedGoogle Scholar
• Abdel-Rahman O , ElsayedZ. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature; Dig. Dis. Sci.58(12), 3389–3396 (2013).
   PubMed Web of Science ®Google Scholar
• Hudes G , CarducciM, TomczakPet al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Finn RS . Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer1(3–4), 247–256 (2012).
   PubMed Web of Science ®Google Scholar
• Huang S , HoughtonPJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs3(2), 295–304 (2002).
   PubMedGoogle Scholar
• Salvadori M . Antineoplastic effects of mammalian target of rapamycine inhibitors. World J. Transplant.2(5), 74–83 (2012).
   PubMedGoogle Scholar
• Funakoshi T , LatifA, GalskyMD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J. Hum. Hypertens.27(10), 601–611 (2013).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O , FouadM. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma; a systematic review of the literature. Crit. Rev. Oncol. Hematol.91(1), 1–8 (2014).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O , FouadM. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta-analysis. Expert Rev. Anticancer Ther.14(6), 751–760 (2014).
   PubMed Web of Science ®Google Scholar
• Sivendran S , AgarwalN, GartrellBet al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat. Rev.40(1), 190–196 (2014).
   PubMed Web of Science ®Google Scholar